Mesoblast

Yahoo Finance • 4 months ago

Is Mesoblast (MESO) The Best Australian Stock To Buy According to Hedge Funds?

We recently published a list of 10 Best Australian Stocks To Buy According to Hedge Funds. In this article, we are going to take a look at where Mesoblast (NASDAQ:MESO) stands against the other Australian stocks. A Look at Australia’s Eco... Full story

Yahoo Finance • 11 months ago

10 Best Australian Stocks To Buy

In this piece, we will take a look at the ten best Australian stocks to buy. If you want to skip our coverage of some of the biggest stocks in Australia and how you might trade them, then you can skip ahead to 5 Best Australian Stocks To B... Full story

Yahoo Finance • last year

Mesoblast Files for Orphan Drug and Pediatric Rare Disease Designations for Rexlemestrocel-L as Treatment for Severe Congenital Heart Disease

NEW YORK, Nov. 26, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has filed for orphan drug designation (ODD) and rare... Full story

Yahoo Finance • last year

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mesoblast Limited - MESO

NEW YORK, Sept. 01, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Mesoblast Limited (“Mesoblast” or the “Company”) (NASDAQ: MESO). Such investors are advised to contact Robert S. Willoughby at n... Full story

Yahoo Finance • 2 years ago

Appendix 4C Quarterly Activity Report

Mesoblast Limited Mesoblast Financial and Operational Highlights for Quarter Ended March 31, 2023 NEW YORK, April 27, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for i... Full story

Yahoo Finance • 2 years ago

Mesoblast Reports Operational and Financial Highlights for Quarter Ended December 31, 2022

Mesoblast Limited NEW YORK, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today reported operational highlights and financial results... Full story

Yahoo Finance • 2 years ago

Children Treated With Remestemcel-L Show Long-Term Survival Through Four Years in Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD)

Key Points: Long-term survival evident through 4 years in children treated with remestemcel-L in Phase 3 trial MSB-GVHD001Overall survival at 2 years was 51% in remestemcel-L treated children and 25-38% in recently published studies of ch... Full story

Yahoo Finance • 2 years ago

Mesoblast Operational and Financial Highlights for Quarter Ended September 30, 2022

NEW YORK, Oct. 30, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an activity report for the fourth quarter ended September 30,... Full story

Yahoo Finance • 3 years ago

Mesoblast Key Opinion Leader Event Series for Investors & Analysts

Mesoblast Limited Chronic Low Back Pain due to Degenerative Disc Disease NEW YORK, June 09, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, will... Full story

Yahoo Finance • 3 years ago

The Rosen Law Firm, P.A. Announces Proposed Class Action Settlement on Behalf of Purchasers of Mesoblast Limited American Depository Shares – MESO

WHITE PLAINS, N.Y., May 23, 2022 (GLOBE NEWSWIRE) -- The Rosen Law Firm, P.A. announce that the United States District Court for the Southern District of New York has approved the following announcement of a proposed class action settlem... Full story